...Cancer ZEN-3694 BET bromodomain proteins Metastatic castration-resistant prostate cancer (CRPC) Phase I $40.9 Eastern Capital; NGN BioMed Opportunity II...

...Private placement Raised: EUR2.8 million ($3.2 million) Shares: 132,079 Shares after offering: 2.1 million Investors: NGN BioMed Opportunity II...